Results 231 to 240 of about 18,518,960 (329)

Medication Error Rate in Transition of Care: General Practitioner (GP) Referrals to a Regional Emergency Department. [PDF]

Healthcare (Basel), 2019
Prior SJ, Cheek C, Cheah D, Etherington C, Williams A, Reeves NS.   +5 more
europepmc   +1 more source

Network Localization of Fatigue in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo, Jaakko Kungshamn, Albert Bellmunt‐Gil, Silvia Tommasin, Abhineet Ojha, Matias Viitala, Juho Aaltonen, Jyrki Lötjönen, Juha Koikkalainen, Pauli Ylikotila, Patrizia Pantano, Merja Soilu‐Hänninen, Juho Joutsa   +12 more
wiley   +1 more source

Assessing the impact of exact reads on reducing the error rate of read mapping. [PDF]

BMC Bioinformatics, 2018
Salari F, Zare-Mirakabad F, Sadeghi M, Rokni-Zadeh H.   +3 more
europepmc   +1 more source

Double symbol error rate and block error rate of MDPSK

Double symbol error rate and block error rate of MDPSK
The double symbol error rate (DSER) is calculated for an M-ary DPSK (MDPSK) system to show that double symbol errors are less likely to be produced when M>or=4 than for the binary case (M=2) and that MDPSK with M>or=4 provides similar conditional SER (defined as the SER when the previous symbol decision was in error) when compared at the same SER value.
openaire  

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

Spin Torque Efficiency and Analytic Error Rate Estimates of Skyrmion Racetrack Memory. [PDF]

Sci Rep, 2019
Suess D, Vogler C, Bruckner F, Heistracher P, Slanovc F, Abert C.   +5 more
europepmc   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Bit Error Rate Closed-Form Expressions for LoRa Systems under Nakagami and Rice Fading Channels. [PDF]

Sensors (Basel), 2019
Ferreira Dias C, Rodrigues de Lima E, Fraidenraich G.   +2 more
europepmc   +1 more source

Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke: A Multicenter Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai, Yang Qu, Reziya Abuduxukuer, Kejia Zhang, Peng Zhang, Xin Tang, Huaimei Zhang, Lijuan Wang, Lichong Yang, Shuangxu Tan, Zhimei Yuan, Ce Han, Lili He, Yuping Zheng, Fenglan Zhao, Lijie Guo, Ligang Jiang, Jinfeng Li, Yongfei Jiang, Xuexia Zou, Dan Xu, Han Xu, Xiaojia Wang, Yingbin Qi, Xuefeng Hu, Yu Zhang, Zhen‐Ni Guo, Hang Jin, on behalf of the Biomarkers of Brain Injury Investigator Study Group   +28 more
wiley   +1 more source

Group sequential crossover trial designs with strong control of the familywise error rate. [PDF]

Seq Anal, 2018
Grayling MJ, Wason JMS, Mander AP.
europepmc   +1 more source